Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The state-of-the-art facility is expected to be commissioned over the next three years
Dr Kinha is a seasoned healthcare and diagnostics leader with over 17 years of experience across leading organisations in the diagnostics sector, with deep expertise in laboratory operations and quality systems
This recognition demonstrate excellence in intellectual property (IP) value creation.
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The move strengthens GBL’s clinical-stage presence in the United States
The company shall process the change of name application with BSE Ltd. in due course
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
Subscribe To Our Newsletter & Stay Updated